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SAMHD1 is a cellular dNTPase that restricts lentiviral infection presumably by lowering cellular dNTP
levels to below a critical threshold required for reverse transcription; however, lowering cellular dNTP
levels may not be the sole mechanism of restriction. In particular, an exonuclease activity of SAMHD1
was reported to contribute to virus restriction. We further investigated the requirements for SAMHD1
restriction activity in both differentiated U937 and cycling HeLa cells. Using hydroxyurea treatment to
lower baseline dNTP levels in HeLa cells, we were able to document efﬁcient SAMHD1 restriction without
signiﬁcant further reduction in dNTP levels by SAMHD1. These results argue against a requirement for
additional myeloid-speciﬁc host factors for SAMHD1 function but further support the notion that
SAMHD1 possesses an additional dNTP-independent function contributing to lentiviral restriction.
However, our own experiments failed to associate this presumed additional SAMHD1 antiviral activity
with a reported nuclease activity.
Published by Elsevier Inc.Introduction
Sterile alpha motif and HD domain protein 1 (SAMHD1) is a host
factor contributing to the inefﬁcient replication of HIV-1 in cells of
myeloid lineage and other non-dividing cell types (Baldauf et al.,
2012; Berger et al., 2011; Descours et al., 2012; Hrecka et al., 2011;
Laguette et al., 2011). The SIVsm/HIV-2 Vpx proteins are however able
to counteract SAMHD1 by targeting it for proteasomal degradation
and viruses lacking this protein are restricted at the reverse tran-
scription step in susceptible cell types (Goujon et al., 2007; Hrecka et
al., 2011; Laguette et al., 2011; Sharova et al., 2008).
Early work on the SAMHD1 protein suggested it to be involved
in regulating the innate immune response as mutations in
SAMHD1 have been associated with Acardi-Goutieres Syndrome
(AGS), a syndrome associated with increased production of inter-
feron alpha (Dussaix et al., 1985; Rice et al., 2009). Accordingly,
SAMHD1 knockout mice, while developmentally healthy, show
increased expression of interferon stimulated genes (Behrendt et
al., 2013; Rehwinkel et al., 2013). The main catalytic activity
ascribed to SAMHD1 is its (d)GTP-dependent dNTPase activity
with an active site located in the protein's HD domain (Amie et al.,
2013; Goldstone et al., 2011; Hansen et al., 2014; Ji et al., 2014,
2013; Koharudin et al., 2014; Powell et al., 2011; Zhu et al., 2013).This enzymatic activity allows SAMHD1 to degrade dNTPs to
component nucleosides and free triphosphate in a single step.
Therefore, dNTP degradation by SAMHD1 provides a counterpart
to dNTP synthesis by ribonucleotide reductase (RNR) with both
these proteins being carefully regulated to control the delicate
dNTP balance in cells (Franzolin et al., 2013). It was thus suggested
that SAMHD1 uses its dNTPase activity to restrict lentivirus (and
other dNTP-dependent virus) infection by decreasing dNTP levels
in susceptible cells to below the levels required for reverse tran-
scription/replication (Hollenbaugh et al., 2013; Kim et al., 2012,
2013; Lahouassa et al., 2012).
Interestingly, SAMHD1 also possesses nucleic acid binding cap-
ability and has been reported in some studies to possess 30–50 exo-
nuclease activity against ssRNA and viral genomes (Beloglazova et al.,
2013; Goncalves et al., 2012; Ryoo et al., 2014; Tungler et al., 2013;
White et al., 2013a). Indeed, several recent reports employing muta-
genesis experiments to genetically separate the dNTPase and nuclease
activities of the protein suggested that nuclease activity may be the
main contributor to SAMHD1 restriction of lentiviruses (Choi et al.,
2015; Ryoo et al., 2014). However, other studies have failed to detect
nuclease activity associated with the SAMHD1 active site (Goldstone
et al., 2011; Seamon et al., 2015) thus, leaving the question of the
functional importance of a SAMHD1 exonuclease activity up for future
investigations. Furthermore, while phosphorylation has been shown
to negatively regulate SAMHD1 restriction ability (Cribier et al., 2013;
Welbourn et al., 2013; White et al., 2013b) it is still unclear whether
this modiﬁcation might affect dNTPase activity, nuclease activity or
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et al., 2015; Ryoo et al., 2014; Tang et al., 2015; Welbourn et al., 2013;
White et al., 2013b; Yan et al., 2015). Therefore, whether lowering
cellular dNTP levels is the sole mechanism of restriction used by
SAMHD1 and whether or not this function is even necessary requires
further investigation.
In this study we investigated the importance of cellular dNTP
levels for virus restriction by SAMHD1. Unlike other restriction factors
such as APOBEC3G that renders normally permissive HeLa cells
restrictive for HIV-1, exogenous expression of SAMHD1 in HeLa cells
shows little to no restrictive phenotype. It is possible that the con-
tinued synthesis of dNTPs in dividing HeLa does not allow SAMHD1
dNTPase activity to sufﬁciently lower the cellular dNTP pool for len-
tiviral restriction to occur. Alternatively, it cannot be ruled out that
SAMHD1 exerts its antiviral effect in conjunction with additional host
factor(s) not expressed in non-myeloid or dividing cell types. To
address these questions, we employed SAMHD1 variants together
with hydroxyurea treatment to modulate dNTP levels in HeLa cells.
Hydroxyurea inhibits ribonucleotide reductase and thus reduces the
cellular dNTP pool at the synthesis step (Nordlund and Reichard,
2006). Determination of cellular dATP levels conﬁrmed that hydro-
xyurea dramatically reduced the baseline dNTP pool in treated HeLa
cells with SAMHD1 exhibiting negligible additional effects on the
dNTP pool. Using the hydroxyurea strategy of lowering baseline dNTP
levels wewere able to demonstrate SAMHD1 antiviral activity in HeLa
cells whereas no additional antiviral activity was demonstrable in
untreated cells. These results suggest that the lack of antiviral activity
of SAMHD1 in normal HeLa cells is not due to the lack of additional
cellular proteins but are due to the high dNTP levels in these cells.
Thus, low cellular dNTP levels appear to be necessary for SAMHD1
restriction activity. However, our results also provide further evidence
that SAMHD1 may possess an additional dNTP-independent function
that contributes to lentiviral restriction but a contribution of a pos-
sible exonuclease activity could not be conﬁrmed.Fig. 1. Effect of SAMHD1 T592 phosphorylation on cellular dATP levels. U937 cells
were transduced with lentiviral particles encoding either WT SAMHD1, the indi-
cated mutants, or an empty vector. Following puromycin selection, cells were dif-
ferentiated overnight with 10 ng/ml PMA. (A) Total cell extracts from differentiated
U937 stable cell lines were separated by SDS-PAGE and subjected to immuno-
blotting for SAMHD1 and actin as indicated. (B) Differentiated cells were infected
with increasing amounts of VSV-G pseudotyped HIV-1-GFP (as described in
(Welbourn et al., 2013)) and the percent infection (% GFP – positive cells) was
determined by ﬂow cytometry 48 h later. (C) Cellular dNTP levels were isolated at
time of infection and amounts of dATP present per million cells were determined
using a polymerase based assay described in the Methods section. Results in panels
A and B are representative of at least 3 independent experiments. Error bars in
panel C represent the mean and standard deviation of quantitation from at least
3 independently generated cell lines.Results and discussion
SAMHD1 T592E decreases dATP levels in cells without causing sig-
niﬁcant restriction
We and others have shown that SAMHD1 phosphomimetics
(T592E/T592D) were unable to restrict HIV infection in PMA-
differentiated U937 cells yet still retained dNTPase activity in vitro
(Welbourn et al., 2013; White et al., 2013b). While other recent studies
have suggested phosphorylation (or phosphomimetics) mightmodulate
dNTPase activity of SAMHD1 under certain conditions using recombi-
nant protein (Arnold et al., 2015; Tang et al., 2015; Yan et al., 2015), only
one group has reported cellular dNTP levels measured in cells under
conditions where the SAMHD1 restrictive phenotype is lost due to
phosphorylation (White et al., 2013b). We therefore wanted to conﬁrm
if the dNTPase activity we observed in vitro translated into a cellular
effect and independently conﬁrm the decreased cellular dNTP levels
seen by others using a phosphomimetic mutant (White et al., 2013b).
U937 cells were therefore transduced with lentiviral particles expres-
sing SAMHD1 variants or empty vector, selected with puromycin, and
differentiated with PMA. Parallel samples were used for western blot
analysis, reporter virus infection, or dNTP isolation. All SAMHD1 var-
iants were efﬁciently expressed (Fig. 1A) and SAMHD1 WT and T592A
were able to efﬁciently restrict HIV-1-GFP infection as compared to cells
expressing the active site mutant (H206R/D207N [HD/RN]) or the
empty vector control (Fig.1B). As reported previously, the T592E protein
was impaired in its ability to restrict HIV-1 infection (Fig. 1B). Cellular
dNTP extraction at time of infection showed that SAMHD1 T592E was
indeed able to decrease cellular dATP levels to a similar extent as the
wildtype and phosphoablative (T592A) proteins as compared to themuch higher levels observed with the active site mutant or empty
vector controls (Fig. 1C). These results therefore independently conﬁrm
that SAMHD1 T592E is able to decrease cellular dNTP levels as efﬁ-
ciently as the WT protein, suggesting an additional mechanism of
restriction by SAMHD1 may exist beyond nucleotide depletion.
Lack of SAMHD1 restriction activity in dividing cells with high dNTP
levels
Although SAMHD1 is present in many actively dividing cell types,
the restrictive effect has generally only been observed in differ-
entiated/non-dividing cells (Baldauf et al., 2012; Berger et al., 2011;
Descours et al., 2012; Hrecka et al., 2011; Laguette et al., 2011; St
Gelais et al., 2012). There are several possible explanations, including
a lowering of set point dNTP levels upon cell differentiation, the
presence of a cell-type speciﬁc co-factor, or modulation of SAMHD1
restriction activity via phosphorylation at T592 in dividing cells
(Cribier et al., 2013; Welbourn et al., 2013; White et al., 2013b). We
Fig. 2. Effect of SAMHD1 on lentiviral infection in dividing cells. HeLa cells were transduced with lentiviral particles encoding either WT SAMHD1, the indicated SAMHD1
mutants, or an empty vector and selected with puromycin for 48 h. (A) Total cell extracts were separated by SDS-PAGE and subjected to immunoblotting for SAMHD1 and
actin as indicated. (B) Cells were infected with increasing volumes of VSV-G-pseudotyped SIV-GFP (White et al., 2013a), with or without Vpx, and the percent infection (%
GFP-positive cells) was determined by ﬂow cytometry 48 h later. (C) Cellular dNTPs were isolated at time of infection and the amount of dATP present per million cells was
determined using a polymerase-based assay. Results in panels A and B are representative of at least 3 independent experiments. Error bars in panel C represent the mean and
standard deviation of quantitation from at least 3 independently generated cell lines.
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lentiviral restriction by SAMHD1. Dividing HeLa cells that express only
low levels of endogenous SAMHD1 were transduced to either express
empty vector, SAMHD1 WT, HD/RN or the phosphoablative T592A
mutant (Fig. 2A). Upon infection with increasing doses of WT or Vpx-
defective SIV-GFP, neither WT SAMHD1 nor the “active” T592A
mutant showed signiﬁcant restriction activity; in fact, efﬁcient infec-
tion was seen with all SAMHD1 variants tested (Fig. 2B). This is
consistent with the lack of SAMHD1 restriction activity observed
toward an HIV-1 reporter in 293T cells or undifferentiated U937 cells
(Arnold et al., 2015; St Gelais et al., 2014). While SAMHD1 WT and
T592A were able to slightly decrease dATP levels compared to the
active site mutant and empty vector control (Fig. 2C), the resulting
levels were still quite high, presumably due to continued dNTP
synthesis in these actively dividing cells. Similarly, St Gelais et al.
(2012) also reported only modest decreases in dNTP levels by the WT
SAMHD1 protein in cycling cells. This lack of restriction activity in
cycling HeLa cells with high dNTP levels, even with the constitutively
active T592A non-phosphorylated variant, suggests that low dNTP
levels may indeed be required for SAMHD1 restriction activity.
Lowering dNTP levels in HeLa cells reveals an additional antiviral
effect of SAMHD1
To explore whether SAMHD1 has additional antiviral effect above
and beyond lowering dNTP levels, we artiﬁcially lowered dNTP levels
in HeLa cells to see if under such conditions SAMHD1 can exert any
extra restriction activity over low dNTPs alone. To do so, HeLa cell
lines expressing SAMHD1 WT, HD/RN, or an empty vector were
generated (Fig. 3A) and treated for 4 h prior to infection withhydroxyurea to block de novo dNTP synthesis by inhibiting ribonu-
cleotide reductase (Nordlund and Reichard, 2006). Fig. 3B shows dATP
levels for dNTPs extracted at time of infection. Similar to Fig. 2, in the
absence of hydroxyurea, WT SAMHD1 decreased dATP levels less
than 2-fold (Fig. 3B), which was not sufﬁcient depletion to restrict
infection by wildtype or Vpx-defective SIV-GFP (Fig. 3C). In contrast,
hydroxyurea treatment reduced dATP levels by about 10-fold even in
the absence of SAMHD1, resulting in globally 3–5 fold lower infection
rates (compare percentage of infection in Fig. 3C and D). Importantly,
in the presence of hydroxyurea, expression of SAMHD1 WT resulted
in an additional 2–3 fold reduction in infection by SIV-GFPΔVpx over
empty vector containing cells (Fig. 3D and E) even though hydro-
xyurea treatment of control cells was able to decrease dATP to levels
approaching those observed when SAMHD1 was also expressed
(Fig. 3B). Signiﬁcantly, this extra restriction was not consistently
observed with the SIV-GFP WT virus that encodes a functional Vpx to
counteract SAMHD1. Slightly lower levels of dATP were consistently
observed in the presence of hydroxyurea when WT SAMHD1 was
present (Fig. 3B). While it cannot be formally ruled out that this dif-
ference contributes to the additional restriction measured, it seems
unlikely this small difference could account for the magnitude of the
effect on viral infection observed. Taking into consideration the results
presented in Fig. 1, these data therefore provide further evidence that
SAMHD1 may possess an additional dNTP-independent function that
can contribute to lentiviral restriction at low dNTP levels.
No SAMHD1 nuclease activity is detected against single-stranded RNA
Several recent reports have suggested nuclease activity as an
important SAMHD1 mechanism of action for viral restriction (Choi et
Fig. 3. Effect of SAMHD1 on lentiviral infection in hydroxyurea-treated cells. HeLa cells were transduced with lentiviral particles encoding either WT SAMHD1, the indicated
SAMHD1 mutants, or an empty vector and selected with puromycin for 48 h. Cells were treated 71 mM hydroxyurea (HU) for 4 h prior to infection or dNTP isolation (in
continued presence or absence of HU). (A) Total cell extracts were separated by SDS-PAGE and subjected to immunoblotting for SAMHD1 and actin as indicated. (B) Cellular
dNTPs were isolated at time of infection and the amount of dATP present per million cells was determined using a polymerase-based assay. Data are presented as mean and
standard deviation of quantitation from at least 3 independently generated cell lines. (C–E) Cells were infected with increasing volumes of VSV-G pseudotyped SIV-GFP, with
or without Vpx, and the percent infection (% GFP-positive cells) was determined by ﬂow cytometry 24 h later. Results in panels A, C, and D show representative results from
one of at least 3 independent experiments. Panel E represents the mean and standard deviation from 3 independent experiments performed as in panel D. The maximum
amount of infection determined in the empty vector sample was deﬁned as 100% for each experiment. All other data points were normalized accordingly.
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SAMHD1 was isolated by immunoprecipitation from PMA-
differentiated U937 cells that had been transduced with lentiviral par-
ticles encoding Flag-tagged WT SAMHD1, SAMHD1 HD/RN, or empty
vector. Of note, the HD/RN mutant was included here because this
dNTPase active site has been reported to be necessary for the SAMHD1
nuclease function (Beloglazova et al., 2013). Eluates containing immu-
noprecipitated SAMHD1 (Fig. 4A) were incubatedwith a 32P-labeled 20-
nucleotide single stranded RNA probe (Ryoo et al., 2014). Reaction
products were separated on denaturing urea-PAGE and visualized by
autoradiography. As shown in Fig. 4B, no SAMHD1-associated nuclease
activity was seen as no increase in degradation products of the radi-
olabeled probe was observed with the isolated WT SAMHD1 protein
over the no protein (mock) control or eluates from empty vector or HD/
RN mutant containing cells. In contrast, an RNase A exonucleasepositive control quantitatively degraded the RNA probe. These data are
consistent with a recent paper that also failed to detect SAMHD1 active-
site associated nuclease activity (Seamon et al., 2015). Degradation of
viral genomic RNA by SAMHD1 nuclease activity as a relevant
mechanism of restriction is also hard to reconcile with a report that
restriction can be relieved even when SAMHD1 degradation by Vpx is
delayed until 24 h post-infection (Hofmann et al., 2013).Conclusions
Overall, the results presented here are consistent with low
dNTP levels being necessary but not sufﬁcient for full SAMHD1
restriction activity. While several recent studies have now shown
phosphorylation to modulate SAMHD1 dNTPase activity in vitro
Fig. 4. SAMHD1 in vitro nuclease assay. U937 cells were transduced with lentiviral
particles encoding 3xFlag-SAMHD1 (WT or HD/RN) or an empty vector. After
puromycin selection, cells were differentiated overnight with PMA and cell extracts
were used for immunoprecipitation using Flag beads followed by elution with
3xFlag peptide. (A) A portion of the eluate was separated by SDS-PAGE and sub-
jected to immunoblotting with SAMHD1-speciﬁc antiserum. (B) The remaining
SAMHD1-containing eluate was incubated at 37 °C with a 20 nucleotide RNA probe
and the reaction products were separated on a 15% denaturing urea polyacrylamide
gel as described in Materials and Methods. * indicates the full length undigested
probe and ** indicates the migration of the products obtained after complete
digestion with the RNaseA positive control.
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iﬁcation still allows residual activity and our data indicate that
SAMHD1 T592E is still able to lower dATP levels in PMA-U937 cells
similar to the WT protein without causing restriction. We were
also unable to conﬁrm SAMHD1 nuclease activity, leaving the
question of what additional SAMHD1 activity is required for full
restriction open for future investigation. Interestingly, the fact that
hydroxyurea treatment in Fig. 3D rendered HeLa cells susceptible
only to wildtype SAMHD1 would argue against a myeloid-speciﬁc
co-factor required for SAMHD1 restriction and would further
suggest that the HD/RN dNTPase active site mutant has also lost its
dNTP-independent function. Therefore, the identiﬁcation of all
factors involved in SAMHD1 restriction of lentiviruses, whether
other co-factors are involved or whether different mechanisms of
action are at play under different conditions or in different cell
types, should remain a subject for future investigations.Materials and methods
Cell culture and transfections
HeLa and 293TN cells were grown in Dulbecco's modiﬁed
Eagles medium (DMEM) containing 10% fetal bovine serum. U937
cells were maintained in RPMI 1640 media containing 10% fetal
bovine serum. U937 cells were differentiated by overnight treat-
ment with 10 ng/ml of phorbol-12-myristate-13-acetate (PMA,
Sigma). Cells were then immediately infected, harvested for wes-
tern blot analysis, or harvested for dNTP isolation and quantita-
tion. For generation of pCDH-SAMHD1 lentiviral transductionparticles, 293TN cells (Systems Biosciences) were transfected
using LipofectAMINE PLUS™ (Invitrogen Corp. Calsbad CA) fol-
lowing the manufacturer's recommendations. For each 25 cm2
ﬂask, 0.67 mg of pCDH plasmid was used together with 6.7 ml of
pPACKH-1 packaging mix (Systems Biosciences). Lentiviral
particle-containing supernatants were collected after 48 h, clar-
iﬁed by ﬁltration through a 0.45 mm ﬁlter and stored at 80 °C.
GFP-HIV-1, SIV-GFP-WT, and SIV-GFP-ΔVpx reporter viruses were
produced from 293TN cells as described (e.g. White et al., 2013a).Antibodies
A polyclonal antibody to human SAMHD1 (SAM416) was
described previously (Welbourn et al., 2012). A polyclonal anti-
body to actin was purchased from Sigma-Aldrich, Inc. (St. Louis
MO; Cat#A-5060) and used as a loading control.Plasmids
The pCDH-SAMHD1 lentiviral expression constructs (WT,
T592A, T592E) were described previously (Welbourn et al., 2013).
The SAMHD1 active site mutant (H206R/D207N, HD/RN) was
generated by quikchange mutagenesis as described for the other
mutants (Welbourn et al., 2013). To generate N-terminally Flag-
tagged lentiviral expression constructs, the SAMHD1 sequence
(WT, HD/RN) was ﬁrst PCR-ampliﬁed from pcDNA-SAMHD1 con-
structs using primers containing EcoRI and Xba1 restriction sites
and inserted into p3xFlagCMV7.1 (Sigma-Aldrich, Inc., St. Louis
MO). The full Flag-SAMHD1 sequence was then ampliﬁed by PCR
using primers containing Bmt1 and BamH1 restriction sites and
inserted into pCDH-CMV-MCS-EF1-puro (Systems Biosciences).Immunoblotting
For immunoblot analysis of cell-associated proteins, whole cell
lysates were prepared as follows: Cells were washed once with
PBS, suspended in PBS and mixed with an equal volume of sample
buffer (4% sodium dodecyl sulfate, 125 mM Tris–HCl, pH 6.8, 10%
glycerol and 0.002% bromophenol blue). Proteins were solubilized
by heating 10–15 min at 95 °C with occasional vortexing to shear
cellular DNA. Cell lysates were subjected to SDS–PAGE; proteins
were transferred to PVDF membranes and reacted with appro-
priate antibodies as described in the text. Membranes were then
incubated with horseradish peroxidase-conjugated secondary
antibodies (GE healthcare, Piscataway NJ) and proteins were
visualized by enhanced chemiluminescence (ECL, GE healthcare,
Piscataway NJ).U937-based HIV-1 restriction assay
HIV-1 restriction assays were performed essentially as descri-
bed (Welbourn et al., 2013; White et al., 2013a). Monocytic U937
cells were transduced with pCDH-SAMHD1 lentiviral particles and
selected with 0.4 mg/ml puromycin for approximately one week.
6104 cells were then differentiated overnight in a 24-well plate
using 10 ng/ml of PMA. The next day, the differentiated cells were
washed and infected with increasing amounts of HIV-1-GFP as
indicated in the text. Fourty-eight hours later, the percentage of
infected cells was determined by ﬂow cytometry for GFP. Cells
were also seeded/differentiated in parallel and harvested for dNTP
isolation at time of infection.
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treatment
HeLa cells were transduced with pCDH-SAMHD1 lentiviral
particles and selected with 3 mg/ml puromycin for 48 h. Cells were
treated 71 mM hydroxyurea (HU, Sigma) for 4 h prior to infection
with increasing amounts of reporter virus or dNTP isolation (in
continued presence or absence of HU). Twenty-four hours later,
the percent infected cells was analyzed by ﬂow cytometry for GFP.
dATP quantitation
dNTPs were isolated from cells essentially as described (Dia-
mond et al., 2004). Cells were harvested, counted, washed twice in
PBS and the cell pellet suspended in ice cold 65% methanol
(100 ml/106 cells). The solution was vortexed for 2 min, boiled for
3 min and then centrifuged for 6 min at 16,000g. The clariﬁed
supernatant was then evaporated to dryness. Pellets were sus-
pended in H2O (100 ml/106 cells) and 2–5 ml extract used for
quantitation. dATP levels were quantiﬁed using the method from
Sherman and Fyfe (Sherman and Fyfe, 1989) as modiﬁed by Fer-
raro et al. (2010) using 32P-dTTP as the probe. In brief, 2–5 ml of
dNTP extract was incubated with 40 mM TrisHCl, pH 7.4, 10 mM
MgCl2, 5 mM dithiothreitol, 0.25 mM oligonucleotide, 1.5 mg RNa-
seA, 0.25 mM labeled dTTP (α-32P dTTP, Perkin Elmer, diluted 1 in
30 with unlabeled dTTP) and 0.025 units Klenow polymerase for
1 h at 37 °C. 15 ml of the reaction mixture was then spotted on
DE81 paper (GE healthcare), washed 3 times 10 min with 5%
Na2HPO4, once with H2O and once with absolute ethanol. The
bound radioactivity was determined by scintillation counting.
These conditions gave a linear standard curve from 0.125 pmol to
4 pmol dATP and the amount of dATP in the extract is expressed as
pmol/106 cells.
Nuclease assay
SAMHD1 proteins used in nuclease assays were isolated from
U937 cells transduced to express 3xFlag-SAMHD1 (WT or HD/RN)
or empty vector. Cells were differentiated overnight with 10 ng/ml
PMA, lysed in 50 mM Tris pH 8.0, 150 mM NaCl, 1% Triton X-100 for
20 min at 4 °C and clariﬁed at 10,000g for 10 min at 4 °C. Cleared
lysates were then incubated for 2 h with anti-Flag conjugated
agarose beads (EZview Red ANTI-FLAG M2 afﬁnity gel, Sigma-
Aldrich) at 4 °C. The samples were then washed twice with wash
buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.1% Triton X-100) and
twice with assay buffer (1x PBS, 2 mM DTT, 10% glycerol, 0.01% NP-
40). Bound proteins were eluted from the beads using 200 ng/ml
3xFlag peptide (ApexBio) in assay buffer. Nuclease assays were
performed using a 32P-labeled 20nt RNA probe as described in
(Ryoo et al., 2014). Immunoprecipitated proteins and the probe
were incubated at 37 °C in assay buffer for up to 3 h. As a positive
control, a sample was treated in parallel with RNaseA (40 mg/ml).
Formamide loading buffer was added, the samples heated to 65 °C
for 5 min and an aliquot of each sample was separated on a 15%
denaturing urea polyacrylamide gel (SequaGel, National Diag-
nostics) prior to autoradiography.Acknowledgments
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